NewLimit raises $435.0M Series C (United States, Jun 2026)
$435.0M
$435 million Series CGenerated social card
Headline
Coinbase CEO’s Longevity Startup NewLimit Raises $435 Million - CoinCentral
About
NewLimit is a longevity biotech startup focused on reversing cellular aging through epigenetic reprogramming. The company aims to develop drugs that reset gene expression in aged cells, with plans to start human clinical trials in 2027 targeting alcohol-related liver disease. This funding round has significantly increased its valuation, reflecting strong investor confidence in its innovative approach.
Article summary
Coinbase CEO’s Longevity Startup NewLimit Raises $435 Million CoinCentral
Founder
Brian Armstrong
CEO & Co-founder
Investors · 3
1 hiddenRelated rounds
| Aug 14, 2026 | MiiHealth AI | $2.8M | — | United States |
| Aug 14, 2026 | Alloy Robotics | $8.0M | Pre-seed | United States |
| Aug 14, 2026 | Zipline | $950.0M | Debt | United States |
| Aug 14, 2026 | InduPro | $77.0M | Series B | United States |